LENZ Therapeutics (LENZ) Scheduled to Post Quarterly Earnings on Wednesday

LENZ Therapeutics (NASDAQ:LENZ) will post its quarterly earnings results before the market opens on Wednesday, November 6th. Analysts expect LENZ Therapeutics to post earnings of ($0.47) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

LENZ Therapeutics (NASDAQ:LENZ) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.09. On average, analysts expect LENZ Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

LENZ Therapeutics Stock Up 0.7 %

Shares of NASDAQ LENZ traded up $0.19 during trading hours on Tuesday, hitting $28.62. The company’s stock had a trading volume of 81,522 shares, compared to its average volume of 134,330. LENZ Therapeutics has a 12 month low of $14.07 and a 12 month high of $31.00. The business has a 50-day simple moving average of $24.16 and a 200-day simple moving average of $20.82.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. William Blair upgraded shares of LENZ Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Piper Sandler reiterated an “overweight” rating and set a $36.00 target price on shares of LENZ Therapeutics in a research note on Thursday, August 15th. Raymond James began coverage on shares of LENZ Therapeutics in a research report on Friday, September 27th. They set an “outperform” rating and a $37.00 price objective for the company. Finally, HC Wainwright began coverage on shares of LENZ Therapeutics in a report on Monday, August 12th. They issued a “buy” rating and a $38.00 target price for the company. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, LENZ Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $35.40.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.